Soluble Periostin is a Potential Surveillance Biomarker for Early and Long-term Response to Chemotherapy in Advanced Breast Cancer

Overview

Journal Cancer Cell Int

Publisher Biomed Central

Date 2024 Mar 20

PMID 38504252

Authors

Li Jia

Wenwei Hu

Xu Yan

Jie Shao

Yuhong Guo

Aimin Zhang

Lianzi Yu

Yunli Zhou

Yueguo Li

Li Ren

Dong Dong

Affiliations

Soon will be listed here.

Abstract

Background: Noninvasive biomarkers for the assessment of response to chemotherapy in advanced breast cancer (BCa) are essential for optimized therapeutic decision-making. We evaluated the potential of soluble Periostin (POSTN) in circulation as a novel biomarker for chemotherapy efficacy monitoring.

Methods: Two hundred and thirty-one patients with different stages of BCa were included. Of those patients, 58 patients with inoperable metastatic disease receiving HER2-targeted or non-targeted chemotherapy were enrolled to assess the performances of markers in recapitulating the chemotherapy efficacy assessed by imaging. POSTN, together with CA153 or CEA at different time points (C0, C2, and C4) were determined.

Results: POSTN levels were significantly associated with tumor volume (P < 0.0001) and TNM stages (P < 0.0001) of BCa. For early monitoring, dynamics of POSTN could recapitulate the chemotherapy efficacy among all molecular subtypes (Cohen's weighted kappa = 0.638, P < 0.0001), much better than that of carcinoembryonic antigen (CEA) and cancer antigen 153 (CA15-3). For early partial response, superior performance of POSTN was observed (Cohen's weighted kappa = 0.827, P < 0.0001) in cases with baseline levels above 17.19 ng/mL. For long-term monitoring, the POSTN response was observed to be strongly consistent with the course of the disease. Moreover, progression free survival analysis showed that patients experienced a significant early decrease of POSTN tended to obtain more benefits from the treatments.

Conclusions: The current study suggests that soluble POSTN is an informative serum biomarker to complement the current clinical approaches for early and long-term chemotherapy efficacy monitoring in advanced BCa.

References

Sher G, Salman N, Khan A, Prabhu K, Raza A, Kulinski M . Epigenetic and breast cancer therapy: Promising diagnostic and therapeutic applications. Semin Cancer Biol. 2020; 83:152-165. DOI: 10.1016/j.semcancer.2020.08.009. View

Duffy M, McDermott E, Crown J . Blood-based biomarkers in breast cancer: From proteins to circulating tumor cells to circulating tumor DNA. Tumour Biol. 2018; 40(5):1010428318776169. DOI: 10.1177/1010428318776169. View

Qin X, Yan M, Zhang J, Wang X, Shen Z, Lv Z . TGFβ3-mediated induction of Periostin facilitates head and neck cancer growth and is associated with metastasis. Sci Rep. 2016; 6:20587. PMC: 4746667. DOI: 10.1038/srep20587. View

Xia L, Hu Q, Zhang J, Xu W, Li X . Survival outcomes of neoadjuvant versus adjuvant chemotherapy in triple-negative breast cancer: a meta-analysis of 36,480 cases. World J Surg Oncol. 2020; 18(1):129. PMC: 7296918. DOI: 10.1186/s12957-020-01907-7. View

Coombes R, Page K, Salari R, Hastings R, Armstrong A, Ahmed S . Personalized Detection of Circulating Tumor DNA Antedates Breast Cancer Metastatic Recurrence. Clin Cancer Res. 2019; 25(14):4255-4263. DOI: 10.1158/1078-0432.CCR-18-3663. View

Roulot A, Hequet D, Guinebretiere J, Vincent-Salomon A, Lerebours F, Dubot C . Tumoral heterogeneity of breast cancer. Ann Biol Clin (Paris). 2016; 74(6):653-660. DOI: 10.1684/abc.2016.1192. View

Takahashi H, Kagara N, Tanei T, Naoi Y, Shimoda M, Shimomura A . Correlation of Methylated Circulating Tumor DNA With Response to Neoadjuvant Chemotherapy in Breast Cancer Patients. Clin Breast Cancer. 2016; 17(1):61-69.e3. DOI: 10.1016/j.clbc.2016.06.006. View

Siravegna G, Marsoni S, Siena S, Bardelli A . Integrating liquid biopsies into the management of cancer. Nat Rev Clin Oncol. 2017; 14(9):531-548. DOI: 10.1038/nrclinonc.2017.14. View

Nakazawa Y, Taniyama Y, Sanada F, Morishita R, Nakamori S, Morimoto K . Periostin blockade overcomes chemoresistance via restricting the expansion of mesenchymal tumor subpopulations in breast cancer. Sci Rep. 2018; 8(1):4013. PMC: 5838092. DOI: 10.1038/s41598-018-22340-7. View

10.

McGuire A, Brown J, Kerin M . Metastatic breast cancer: the potential of miRNA for diagnosis and treatment monitoring. Cancer Metastasis Rev. 2015; 34(1):145-55. PMC: 4368851. DOI: 10.1007/s10555-015-9551-7. View

11.

Nuzzo P, Rubagotti A, Zinoli L, Salvi S, Boccardo S, Boccardo F . The prognostic value of stromal and epithelial periostin expression in human breast cancer: correlation with clinical pathological features and mortality outcome. BMC Cancer. 2016; 16:95. PMC: 4752779. DOI: 10.1186/s12885-016-2139-y. View

12.

Eisenhauer E, Therasse P, Bogaerts J, Schwartz L, Sargent D, Ford R . New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2008; 45(2):228-47. DOI: 10.1016/j.ejca.2008.10.026. View

13.

Jia L, Li G, Ma N, Zhang A, Zhou Y, Ren L . Soluble POSTN is a novel biomarker complementing CA153 and CEA for breast cancer diagnosis and metastasis prediction. BMC Cancer. 2022; 22(1):760. PMC: 9281047. DOI: 10.1186/s12885-022-09864-y. View

14.

Lei S, Zheng R, Zhang S, Chen R, Wang S, Sun K . Breast cancer incidence and mortality in women in China: temporal trends and projections to 2030. Cancer Biol Med. 2021; . PMC: 8330522. DOI: 10.20892/j.issn.2095-3941.2020.0523. View

15.

Dong D, Jia L, Zhang L, Ma N, Zhang A, Zhou Y . Periostin and CA242 as potential diagnostic serum biomarkers complementing CA19.9 in detecting pancreatic cancer. Cancer Sci. 2018; 109(9):2841-2851. PMC: 6125476. DOI: 10.1111/cas.13712. View

16.

Crowley E, Di Nicolantonio F, Loupakis F, Bardelli A . Liquid biopsy: monitoring cancer-genetics in the blood. Nat Rev Clin Oncol. 2013; 10(8):472-84. DOI: 10.1038/nrclinonc.2013.110. View

17.

Schwarzenbach H, Pantel K . Circulating DNA as biomarker in breast cancer. Breast Cancer Res. 2015; 17(1):136. PMC: 4599311. DOI: 10.1186/s13058-015-0645-5. View

18.

Van Poznak C, Harris L, Somerfield M . Use of Biomarkers to Guide Decisions on Systemic Therapy for Women With Metastatic Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Oncol Pract. 2018; 11(6):514-516. DOI: 10.1200/JOP.2015.005215. View

19.

Zhang Y, Zhang G, Li J, Tao Q, Tang W . The expression analysis of periostin in human breast cancer. J Surg Res. 2009; 160(1):102-6. DOI: 10.1016/j.jss.2008.12.042. View

20.

Siegel R, Miller K, Jemal A . Cancer statistics, 2018. CA Cancer J Clin. 2018; 68(1):7-30. DOI: 10.3322/caac.21442. View